Cap: $48.9M
Runway: Q1 2027
Clinical Pipeline (Compendium View)
| Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|
| RAD 101 (Pivalate) | Brain Metastases Imaging | Phase 2b | Full 30-Patient Dataset: June 2026 |
| RAD 204 | PD-L1 Positive NSCLC | Phase 1 | Cohort 3 Enrollment: Q2 2026 |
Latest SEC Filings
Active Clinical Trials
Operational Overview
Operational Overview
A multi-modality radiopharma player with a very tight market cap. The recent interim data for RAD 101 showed a 90% concordance with MRI, which is an institutional-grade validation of their diagnostic platform.
Risk/Reward
Very low liquidity. The primary risk is the high cash burn ($~22M per half-year), but the Fast Track designations provide a “greased” regulatory pathway that larger peers lack.